Document is current
Any future updates will be listed below
-
Authors
Floryan, Marie
Cambria, Elena
Blazeski, Adriana
Coughlin, Mark F.
Wan, Zhengpeng
Offeddu, Giovanni
Vinayak, Vinayak
Kant, Aayush
Whisler, Jordan
Shenoy, Vivek
Kamm, Roger D.
-
Funding
Funding for this research was provided by:
National Cancer Institute (U54-CA261694, U54-CA261694, U54-CA261694, U54-CA261694, U54-CA261694, U54-CA261694, U54-CA261694, U54-CA261694)
Swiss National Science Foundation (P2EZP2_199914)
- License Information
-
More Information
Article History
Received: 6 December 2024
Accepted: 3 September 2025
First Online: 4 November 2025
Competing interests
: R.D.K. is a co-founder of AIM Biotech, a company that markets microfluidic technologies and receives research support from Amgen, AbbVie, Boehringer-Ingelheim, GSK, Novartis, Roche, Takeda, Eisai, EMD Serono and Visterra. None of these activities is related to the content of this article. The other authors declare no competing interests. All other authors declare no financial competing interests.
